RXRX vs. GSK
Compare and contrast key facts about Recursion Pharmaceuticals, Inc. (RXRX) and GlaxoSmithKline plc (GSK).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: RXRX or GSK.
Performance
RXRX vs. GSK - Performance Comparison
Returns By Period
In the year-to-date period, RXRX achieves a -38.74% return, which is significantly lower than GSK's -6.46% return.
RXRX
-38.74%
-10.65%
-35.47%
-7.65%
N/A
N/A
GSK
-6.46%
-11.61%
-25.62%
-2.01%
-1.39%
1.52%
Fundamentals
| RXRX | GSK | |
|---|---|---|
| Market Cap | $1.80B | $68.27B |
| EPS | -$1.54 | $1.54 |
| Total Revenue (TTM) | $65.18M | $31.27B |
| Gross Profit (TTM) | $1.96M | $22.46B |
| EBITDA (TTM) | -$366.27M | $7.73B |
Key characteristics
| RXRX | GSK | |
|---|---|---|
| Sharpe Ratio | -0.15 | -0.06 |
| Sortino Ratio | 0.38 | 0.07 |
| Omega Ratio | 1.04 | 1.01 |
| Calmar Ratio | -0.14 | -0.05 |
| Martin Ratio | -0.28 | -0.13 |
| Ulcer Index | 42.94% | 9.69% |
| Daily Std Dev | 82.24% | 21.55% |
| Max Drawdown | -88.97% | -55.21% |
| Current Drawdown | -85.39% | -25.62% |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Correlation
The correlation between RXRX and GSK is 0.10, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Risk-Adjusted Performance
RXRX vs. GSK - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Recursion Pharmaceuticals, Inc. (RXRX) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
RXRX vs. GSK - Dividend Comparison
RXRX has not paid dividends to shareholders, while GSK's dividend yield for the trailing twelve months is around 4.67%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
RXRX Recursion Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
GSK GlaxoSmithKline plc | 4.67% | 3.75% | 4.78% | 4.92% | 5.49% | 4.28% | 5.55% | 5.72% | 7.06% | 5.96% | 6.09% | 4.43% |
Drawdowns
RXRX vs. GSK - Drawdown Comparison
The maximum RXRX drawdown since its inception was -88.97%, which is greater than GSK's maximum drawdown of -55.21%. Use the drawdown chart below to compare losses from any high point for RXRX and GSK. For additional features, visit the drawdowns tool.
Volatility
RXRX vs. GSK - Volatility Comparison
Recursion Pharmaceuticals, Inc. (RXRX) has a higher volatility of 21.14% compared to GlaxoSmithKline plc (GSK) at 6.22%. This indicates that RXRX's price experiences larger fluctuations and is considered to be riskier than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
RXRX vs. GSK - Financials Comparison
This section allows you to compare key financial metrics between Recursion Pharmaceuticals, Inc. and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities